Yuxin Ma, Xinhong Shi, Kun Zhao, Shuyi Hu, Yue Shi, Yingying Jiang, Yiling Liu, Lin Lu, Yuting Chang, Fei Zhou, Yingying Dai, Zipeng Wu, Shiyi Li, Zhiying Qian, Xia Xu, Chenchen Li, Bo Shen, Guoren Zhou, Cheng Chen, Xiaohua Wang, Jifeng Feng
Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients...
2024: Frontiers in Oncology